Author Question: Following release from the presynaptic cell, neuropeptides a. cannot be deactivated by enzymes, ... (Read 19 times)

ENagel

  • Hero Member
  • *****
  • Posts: 540
Following release from the presynaptic cell, neuropeptides
 
  a. cannot be deactivated by enzymes, whereas small-molecule transmitters diffuse away or are deactivated by reuptake.
  b. are deactivated by reuptake, whereas small-molecule transmitters diffuse away or are deactivated by enzymes.
  c. can diffuse away from synapses, whereas small-molecule transmitters are deactivated by reuptake.
 d. and small-molecule transmitters can be deactivated by diffusion, enzymes, or reuptake.

Question 2

The release of vesicles containing neuropeptides requires
 
  a. higher levels of calcium than the release of small-molecule neurotransmitters.
 b. lower levels of calcium than the release of small-molecule neurotransmitters.
 c. approximately equal levels of calcium as the release of small-molecule neurotransmitters.
  d. no calcium at all.



leannegxo

  • Sr. Member
  • ****
  • Posts: 374
Answer to Question 1

c

Answer to Question 2

a



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
 

Did you know?

For about 100 years, scientists thought that peptic ulcers were caused by stress, spicy food, and alcohol. Later, researchers added stomach acid to the list of causes and began treating ulcers with antacids. Now it is known that peptic ulcers are predominantly caused by Helicobacter pylori, a spiral-shaped bacterium that normally exist in the stomach.

Did you know?

During pregnancy, a woman is more likely to experience bleeding gums and nosebleeds caused by hormonal changes that increase blood flow to the mouth and nose.

Did you know?

In ancient Rome, many of the richer people in the population had lead-induced gout. The reason for this is unclear. Lead poisoning has also been linked to madness.

Did you know?

The human body produces and destroys 15 million blood cells every second.

Did you know?

As of mid-2016, 18.2 million people were receiving advanced retroviral therapy (ART) worldwide. This represents between 43–50% of the 34–39.8 million people living with HIV.

For a complete list of videos, visit our video library